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Background: Trial sequential analysis (TSA) may establish when firm evidence about the efficacy of interventions is
reached in a cumulative meta-analysis, combining a required information size with adjusted thresholds for
conservative statistical significance. Our aim was to demonstrate TSA results on randomized controlled trials
(RCTs) included in a Cochrane systematic review on the effectiveness of constraint-induced movement therapy
(CIMT) for stroke patients.
Methods: We extracted data on the functional independence measure (FIM) and the action research arm test (ARAT)
from RCTs that compared CIMT versus other rehabilitative techniques. Mean differences (MD) were analyzed using a
random-effects model. We calculated the information size and the cumulative Z-statistic, applying the O’Brien-Fleming
monitoring boundaries.
Results: We included data from 14 RCTs. In the conventional meta-analysis (seven trials, 233 patients), the effect of
CIMT on FIM was reported as significant (MD 2.88, 95% CI 0.08 to 5.68; P = 0.04). The diversity-adjusted required
information size was 142 patients, and the cumulative Z-score did not cross the trial sequential monitoring
boundary for benefit (adjusted 95% CI −0.02 to 5.78). The effect of CIMT on ARAT (nine trials, 199 patients)
was reported as significant (MD 7.78, 95% CI 1.19 to 14.37; P = 0.02). However, the diversity-adjusted required
information size was 252 patients, and the Z-score did not cross the trial sequential monitoring boundary for benefit
(adjusted 95% CI −0.06 to 15.62).
Conclusions: Although conventional meta-analyses of CIMT reached statistical significance, their overall results remain
inconclusive and might be spurious. Researchers should not be overconfident on CIMT efficacy based on the results of
meta-analyses and derived recommendations.
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Trial sequential analysis (TSA) is a methodology used to
control for random errors in meta-analyses in order to
critically appraise the effect of an intervention on a given
outcome [1]. Conventional meta-analyses have a risk of
false positive, neutral, or negative results that may lead
to inaccurate conclusions regarding treatment effects
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testing when updating meta-analyses with new trials
[1,5]. The latter risk can be assessed by several methods
of testing (for example, when a multitude of interim ana-
lyses are conducted) in a single randomized controlled
trial (RCT) [3,5-7]. Spurious findings in meta-analyses
can also result from systematic error (bias) due to defi-
ciencies in study design and conduct such as inadequate
randomization, lack of blinding, selective outcome report-
ing bias, and small study bias (which may be a proxy for
the other bias mechanisms) [5,8,9]. Random errors and
systematic errors can produce inaccurate and over-preciseal. This is an Open Access article distributed under the terms of the Creative
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overemphasize the real effectiveness of the investigated
intervention. Although the scientific community has
invested much efforts to expose the pitfalls of system-
atic errors (bias) in meta-analyses [5,8,9], it has largely
ignored the issues of required information size and the
risks of random errors in meta-analyses [1,5,10].
For each RCT, the number of events and patients required
to make a reliable statistical inference must be estimated
(the sample size guaranteeing sufficient power 1 – beta (the
risk of type II error) to accept or rejects a certain interven-
tion effect, which implies the clinically important target dif-
ference between the intervention groups and the standard
deviation of the measurements, at a chosen risk of alpha
(type I error)) [11]. Similarly, in order to control for the risk
of random error, meta-analyses should include the calcula-
tion of a required information size, which is at least the sam-
ple size of an adequately powered single trial [10,12,13]. For
continuous outcomes, the required information size of
meta-analyses is based on: the minimal importance differ-
ence (MID) (a priori assumed intervention effect); standard
error of the outcome; desired maximum risk of a false posi-
tive result (type I error, usually set as alpha = 0.05); and
desired maximum risk of a false negative result (type II
error, usually set as beta = 0.20 or 0.10) [1,11]. The required
information size of meta-analyses additionally depends on
the amount of heterogeneity across the trials in the meta-
analysis [14].
In systematic reviews, meta-analyses are commonly re-
peated to integrate accumulating data from newly pub-
lished trials. Cochrane reviews, for example, require the
regular updating of analyses to reflect current research.
A statistically significant finding, however, is more likely
in repeated analyses such that the actual risk of type I
error in meta-analyses increases to between 10 and 30%
[15-17]. Given this, retaining P values of less than 0.05
as evidence of ‘statistical significance’ can be highly mis-
leading in meta-analyses that have not reached their re-
quired information size. A false positive result can be
avoided by adjusting the threshold for statistical signifi-
cance using conservative TSA monitoring boundaries,
which are analogous to interim monitoring in a single
RCT [1,3,13]. These monitoring boundaries are more
conservative than conventional statistical boundaries,
and adapt as new trials are published and meta-analyses
are updated over time. TSA may quantify the reliability
of the cumulative data in meta-analyses and provide im-
portant information on the number of additional pa-
tients required in future RCTs to reach ‘firm evidence’, a
more reliable statistically significant results about the su-
periority, neutrality, or inferiority of the intervention.
The total number of patients needed across included
studies and future trials in order to reach this conclusion
is called the required information size [1]. TSA showsthe potential to be more reliable, supporting balanced
interpretation of the overall effect size obtained by trad-
itional meta-analysis techniques [10,13].
The present study demonstrates TSA applied to a neu-
rorehabilitation technique called constraint-induced move-
ment therapy (CIMT). CIMT promotes the functional
recovery of the upper arm in stroke patients through
the forced use of the paretic limb; this is achieved by
restraining the sound limb with a glove and special
armrest [18-20]. Our updated Cochrane review with
conventional meta-analyses reported a statistically sig-
nificant effect of CIMT on arm motor function as mea-
sured through the Action Research Arm Test (ARAT),
and a non-statistically significant effect on disability
using the Functional Independence Measure (FIM) [4].
The majority of the trials, however, featured major
risks of bias. Thus, the statistically significant findings
may be attributed to systematic error (bias) and ran-
dom error (play of chance), or represent a true treat-
ment effect.
In our present study, we considered these risks of bias
in the calculation of the required information size, but
disregarded them when applying TSA to the RCTs com-
paring CIMT with traditional rehabilitation in stroke pa-
tients [21]. We critically appraised the results of our
Cochrane review to determine whether firm evidence could
be reached regarding the efficacy of CIMT on disability and
arm motor function. If the data were inconclusive, we cal-
culated the number of patients needed in future RCTs to at-
tain the required information size or reach the area of
futility. We aimed to illustrate the importance of accounting
for the risk of random error in cumulative meta-analyses,
and to provide a tool for quantifying the amount of add-
itional evidence required to reach firm evidence. Moreover,
we sought to demonstrate to authors of meta-analyses that
the incorporation of TSA can lead to more conservative re-
sults, thereby avoiding the premature conclusion of treat-
ment efficacy or non-efficacy.
Methods
This manuscript is based on an update of a Cochrane
systematic review published in The Cochrane Library
[4]. Briefly, we analyzed RCTs or quasi-randomized stud-
ies that compared CIMT to other rehabilitative tech-
niques (physical therapy or occupational therapy). To be
included in the review, participants had to be older than
18 years of age with a diagnosis of ischemic or hemorrhagic
stroke and upper limb paresis with sustained ability to
move the affected hand. The search strategy is available in
the Appendix. We considered all types of CIMT, irre-
spective of the number of hours of training per day,
number of hours of constraint per day, duration of
treatment, and type of exercise used in the training
section. Two independent reviewers (GC and DC) extracted
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any disagreements.
In the updated review, for analyses on disability, we fo-
cused on data using the FIM [22]; for arm motor function,
we extracted data measured by the ARAT (the original re-
view did not specify FIM and ARAT in the inclusion cri-
teria thus the updated review excluded all trials in the
original review using different outcomes measure scales.)
[23]. We decided to select these outcomes because the
aim of CIMT is to improve functional recovery and poten-
tial motor ability. Upper extremities are important to most
daily activities, making it difficult to select a measure that
considers all types of activities. FIM refers to a measure-
ment of global disability; it can be used to represent func-
tional activities involving the upper extremities (such as
eating, bathing, and dressing) of a patient. Because some
trials might have adopted modified versions of FIM and
ARAT with a different number of items, we estimated the
FIM score for each study (scores presented in the studies
were divided by the total score of the subscales or items
used). To better evaluate upper extremities, we assessed
the quality of movement and functionality with ARAT,
which was reported in most RCTs included in the original
review and its update [4,21].
Risk of bias assessment
We used all the Cochrane Handbook domains for asses-
sing the risk of bias [24]. We sub-grouped trials accord-
ing to the level of risk of bias based on the most recent
risk of bias assessment in the updated review according
to the Cochrane Handbook of Systematic Reviews of In-
terventions [5]. Two independent reviewers (GC and
DC) assessed the risk of bias; disagreements were resolved
by consulting a third author (LM). We decided to rate
RCTs as at a lower risk of bias when the domains se-
quence generation, concealment of allocation, and blind-
ing were adequate, even if other domains were with high
risk of bias. An RCT was evaluated as having a high risk
of bias if one or more of these domains were judged to be
at a high risk of bias, or when the reporting was unclear.
Statistical methods
Meta-analysis
Data were summarized as a mean difference (MD) with
95% confidence intervals (CI) using Review Manager
(RevMan version 5.0.25 The Cochrane Collaboration,
Copenhagen:The Nordic Cochrane Centre, Denmark,
2014.) [25]. The inconsistency (I2) statistic and the diver-
sity (D2) statistic were used to assess the degree of het-
erogeneity among trials in each analysis [5,14]. Data
were summarized in a meta-analysis using the random-
effects models described by DerSimonian and Laird [26],
irrespective of I2 values, assuming clinical heterogeneity
to be compelling in this clinical setting due todifferences in the types of patient populations (for ex-
ample, stroke severity), interventions (duration and inten-
sity), and controls (for example, differences in standard
physiotherapies).
Trial sequential analysis
For each meta-analysis, we calculated the diversity-
adjusted required information size and applied trial se-
quential monitoring boundaries with TSA version 0.9
beta (Copenhagen Trial Unit, Centre for Clinical Inter-
vention Research, Copenhagen, Denmark. 2011) [13].
The information size was based on an alpha of 0.05, a
beta of 0.20 (power of 80%), the variance of the interven-
tion effect between studies, and the MID. The methods
used to determine the MID are presented in the
‘Methods to estimate the MID in the TSA’ section. We
set the conservative trial monitoring boundaries by
Lan-DeMets-O’Brien-Fleming as the α-spending func-
tion [1,27]. We calculated the cumulative Z-curve of
each cumulative meta-analysis and plotted it against
the above monitoring boundaries according to the
random-effects models. In general, one of the following
TSA results may occur. The crossing of the cumulative
Z-curve (the series of Z-statistics after each consecutive
trial) into the trial sequential monitoring boundary for
benefit indicates that a sufficient level of evidence has
been reached, and no further trials may be needed to
demonstrate the superiority of the intervention. If the
cumulative Z-curve does not cross any of the trial se-
quential monitoring boundaries, however, there is likely
insufficient evidence to reach a conclusion, and add-
itional trials may be required [10,28]. Here, the ques-
tion concerns whether the Z-curve has reached the
futility area. If not, the TSA can provide additional in-
formation on the size (number of patients) of future
RCTs to reach a definitive conclusion. In our study, we
compared Z-scores obtained from TSA and RevMan to
check for potential inconsistencies.
Methods to estimate the minimal important difference in
the trial sequential analysis
MID has been defined as ‘the smallest difference in score in
the domain of interest that patients perceive as important, ei-
ther beneficial or harmful, and which would lead the clinician
to consider a change in the patient’s management’ [29]. The
magnitude of the MID is linked to the intervention effect size,
and their relationship determines the clinical relevance of an
intervention. There are two methods to establish the MID.
The first and preferred method, the ‘anchor-based approach’,
is used when the MID is derived from a study that is evaluated
as interpretable, valid, and generalizable [30]. In this case, a
low-cost intervention without adverse effects would likely be
used even if the MID was low. Alternatively, an expensive
intervention with potential adverse events would only be of
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bution-based approach’ [31,32], may assume that a change
equal to 0.5 of the standard deviation on the instrument score
is representative of the ‘true’ MID. An effect size of 0.5 of the
standard deviation is usually described as a moderate effect
size [33].The MID can be estimated by multiplying the effect
size of 0.5 by the pooled standard deviation between groups.
The formulas to calculate the effect size and the pooled stand-
ard deviation are provided below [34]:
ES
 ¼
XG1−XG2
Spooled
ð1Þ
Where ES is effect size, XG1 is mean group 1, XG2 is
mean group 2, and Spooled is pooled standard deviation.
To calculate the pooled standard deviation, the follow-
ing formula is used:
Spooled ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
S21 n1−1ð Þ þ S22 n2−1ð Þ
q
n1 þ n2−2 ð2Þ
Where S1 is standard deviation group 1, S2 is standard
deviation group 2, n1 is the sample size for group 1, n2
is the sample size for group 2.
MID0:5 of the standard deviation is equal to 0:5
 Spooled baseline: ð3Þ
Preferably, the reference standard MID should be
established by the anchor-based method rather than the
distribution-based method. The anchor-based method
reflects the point of view of the patients [35,36], while
the distribution-based method may not. If an RCT pre-
sented an anchor-based MID that was positively evalu-
ated by the authors, we used this value. Otherwise, we
implemented the distribution-based method.
Results
We excluded four [37-40] of the 18 trials included in the
updated Cochrane Systematic Review [4] as they did not
report on the two selected outcomes (FIM and ARAT).
Accordingly, we included 14 trials in our present study
reporting either FIM or ARAT. Figure 1 shows the study
flow. The characteristics of the trials are available in the
original and updated reviews [4,21].
Risk of bias assessment
All the included trials were at high risk of bias (Table 1).
Four trials were not adequately randomized [41-44] and
only three were adequately concealing the allocation
[45-47]. A total of 13 trials claimed to have blinded the
outcome assessment, however, the blinding may have
been compromised by inadequate randomization. Three
trials were at lower risk of bias due to adequate
randomization and blinding [45-47].Disability - Functional Independence Measure
Eight out of 14 trials were included in our study assessed
disability; seven trials [42,44,46-50], comprising 233 pa-
tients with stroke, assessed disability through FIM or its
modified version, and one RCT [45] assessed disability
through another scale, the Barthel Index, and was ex-
cluded. Meta-analysis of CIMT versus traditional re-
habilitation showed a statistically significant benefit of
CIMT on FIM (random-effects model, MD 2.88 points,
95% CI 0.08 to 5.68; I2 = 24%) (Figure 2).
Although one study had an established MID based on
the anchor-based approach [51], its population did not
follow our inclusion criteria: stroke patients included in
our review had a higher initial FIM score, which was ne-
cessary to be able to perform the CIMT technique. We
found one study in the literature that estimated an MID
for stroke patients of 22 points on the total FIM (total is
126 points) [51]. However, such improvement is not
plausible in patients with a high initial FIM score; in
other words, the higher the FIM score, the least likely
that the MD is clinically evident. Therefore, a
distribution-based approach was performed to determine
the MID. We selected the study by Lin et al. [47] as the
best trial candidate to derive the MID; it had a lower risk
of bias and acceptable external validity. The estimated
MID was 7.85 points. If we do not consider the risks of
bias, the diversity-adjusted required information size cal-
culated was 142 patients (Figure 3). If the risks of bias
are disregarded, the TSA supported the acceptance of
CIMT as an effective intervention to improve FIM; with
the publication of the sixth trial, the cumulative Z-curve
crossed the information size and the trial sequential
monitoring boundary for benefit. However, the subse-
quently published RCTs had less extreme results
compared to the first studies and moved the cumulative
Z-curve back toward the no-difference line, raising doubts
about the conclusiveness of the information size on the
potential benefit of CIMT on FIM. The final cumulative
Z-score did not cross the trial sequential monitoring
boundary for benefit (adjusted 95% CI −0.02 to 5.78).
Arm motor function - Action Research Arm Test
Nine trials [41-43,45,49,52-55], totaling 199 patients,
assessed arm motor function using ARAT; five RCTs were
excluded because one [48] assessed motor function
through the Wolf Motor Function Test (WMFT) and four
trials did not assess arm motor function [44,46,47,50].
Meta-analyses showed a statistically significant CIMT ef-
fect on arm motor function (random effects, MD 7.78
points, 95% CI 1.19 to 14.37; I2 = 85%) (Figure 4).
An anchor-based approach was used to determine the
MID in the RCT by Lang et al. [56]. The estimated MID
was 12 points, corresponding to the diversity-adjusted
required information size of 252 patients (Figure 5). If
Figure 1 Flow diagram of trials presenting selection for inclusion. Of the 14 trials included in the trial sequential analyses, two assessed both
disability and arm motor function through FIM and ARAT, respectively. Abbreviations: FIM, Functional Independence Measure; ARAT, Action Research
Arm Test; TSA, Trial Sequential Analysis. 1. Corbetta D, Sirtori V, Moja L, Gatti R: Constraint-induced movement therapy in stroke patients: systematic
review and meta-analysis. Eur J Phys Rehabil Med 2010.
Table 1 Risk of bias assessment of included randomized and quasi-randomized controlled trials
Trial Sequence generation Allocation concealment Blinding of assessors Lower or high risk of bias
Atteya et al. [41] Inadequate Unclear Adequate Highb
Dahl et al. [48] Adequate Unclear Adequate High
Dromerick et al. [52] Adequate Unclear Adequate High
Dromerick et al. [42] Inadequate Unclear Adequate High
Hammer and Lindmark [53] Adequate Unclear Inadequate High
Lin et al. [47] Adequate Adequate Adequate Lowera
Lin et al. [46] Adequate Adequate Adequate Lower
Myint et al. [45] Adequate Adequate Adequate Lower
Page et al. [43] Inadequate Unclear Adequate High
Page et al. [55] Adequate Unclear Adequate High
Page et al. [54] Adequate Unclear Adequate High
Ploughman and Corbett [49] Adequate Unclear Adequate High
Wu et al. [44] Inadequate Unclear Adequate High
Wu et al. [50] Adequate Unclear Adequate High
aLower risk of bias when the domains sequence generation, concealment of allocation, and blinding of assessors were adequate.
bHigh risk of bias when one or more of these domains were judged as inadequate or the reporting was unclear.
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Figure 2 Meta-analysis of constraint-induced movement therapy (CIMT) versus control on disability (FIM). Effect of CIMT compared with
usual care on disability, assessed using Functional Independence Measure (FIM) in adult stroke patients. The meta-analysis included 233 stroke
patients. The black diamond does not cross the vertical line and showed an effect size of 2.88 (95% confidence interval 0.08 to 5.68), which is only
significant (P = 0.04) using conventional meta-analytic methods. Heterogeneity expressed as I2 was 24%. Abbreviations: CIMT, Constraint induced
movement therapy; FIM, Functional independence measure.
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crossed the trial sequential monitoring boundaries after
the fifth trial, demonstrating a significant intervention
effect. However, the final cumulative Z-score did not
cross the trial sequential monitoring boundary for bene-
fit (adjusted 95% CI −0.06 to 15.62).
Although CIMT looked promising during the fifth,
sixth, and seventh trials, the intervention no longer
showed a statistically significantly effect on ARAT in the
eighth and ninth published trials. Additional patients
(increased from 199 to 252), might provide more evi-
dence to either accept or reject an effect of CIMT on
ARAT, decreasing doubts about CIMT consistency.Figure 3 Trial sequential analysis of constraint-induced movement th
required information size of 142 patients calculated on basis of 7.50 MID of
(D or rather D2) of 50%. The blue cumulative Z-curve crosses the inward slo
required information size. The horizontal green lines illustrate the conventi
intersected after the third trial. Although with 199 patients randomized we
seventh trial, the cumulative Z-score comes back toward the null effect, jus
and the figure were performed with TSA software. Legend. Square symbol:
boundary for benefit score for single study. Abbreviations: DARIS, diversity-ad
variance; D, diversity; a, alpha; b, beta.Discussion
The implications of our Cochrane review on the effect-
iveness of CIMT for practice were limited by numerous
underpowered studies with a small sample size. Further-
more, the results could have been influenced by system-
atic error in studies with a high risk of bias as well as
random errors [1]. Our conventional meta-analysis of
the primary outcome, disability, in the updated review
showed no statistically significant effect of CIMT on
FIM, in contrast with our observation in the previous
version of the review. A meta-analysis on a secondary
outcome, arm motor function, showed a moderate statis-
tically significant effect on ARAT [4]. We felt that ourerapy (CIMT) versus control for disability (FIM). Diversity-adjusted
FIM (see text); variance of 126.31; alpha = 5%; beta = 20%, and diversity
ping red trial sequential monitoring boundary for benefit and the
onal level of statistical significance (two-sided alpha = 0.05), which was
have sufficient evidence to accept an effect of CIMT on FIM, after the
t above the trial sequential monitoring boundaries score. The analysis
z-score for single study; Diamond symbol: trial sequential monitoring
justed required information size; MID, minimal important difference; var,
Figure 4 Meta-analysis constraint-induced movement therapy (CIMT) versus control on arm motor function (ARAT). Effect of CIMT
compared with usual care on arm motor function, assessed using Action Research Arm Test (ARAT) in adult stroke patients. The meta-analysis
included 199 stroke patients. The black diamond does not cross the vertical line and showed an effect size of 7.78 (95% CI 1.19 to 14.37), which is
significant (P = 0.02) using conventional meta-analytic methods. Heterogeneity expressed as I2 85% was high. Abbreviations: CIMT, Constraint
induced movement therapy; ARAT, action research arm test.
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published RCT, which led to the appearance of spuriously
favorable results in our primary meta-analysis. In the
present study, meta-analyses and TSAs were used to bet-
ter explore the evidence on the effects of CIMT on disabil-
ity and arm motor function in patients with stroke.
Although the results of the meta-analysis on the primary
outcome were statistically significant, the clinical relevance
was questionable due to the small effect size. In fact, for
the disability outcome, the TSA data suggested that the in-
formation size was sufficient. The cumulative Z-score,
however, moved towards null effect, while a few additionalFigure 5 Trial sequential analysis constraint-induced movement thera
adjusted required information size of 252 patients calculated on basis of 12
(D or rather D2 of 91%). The blue cumulative Z-curve crosses first the horiz
during the second trial and then crossed the inward sloping red trial seque
ninth trial, the cumulative Z-score for 199 patients of 2.31 is just below the
252 (79.0%) patients randomized we still have insufficient evidence to acce
during the fifth, sixth, and seventh trials (disregarding the risks of bias). The
Square symbol: z-score for single study; Diamond symbol: trial sequential m
DARIS, diversity-adjusted required information size; MID, minimal importantpatients seemed necessary to reach firm conclusion on the
arm motor function outcome. More evidence on treat-
ment efficacy is required to decrease the socioeconomic
burden of this pathological condition. We chose to explore
disability and arm motor function as the main outcomes
due to their importance not only for patients and their
quality of life, but also for clinicians, families, healthcare
systems, and society. An effective treatment that decreases
disability level and increases arm motor function can im-
prove patient ability in daily life, their life satisfaction, and
quality of life, and reduce family load, social assistance,
hospitalization, and economic social charge.py (CIMT) versus control for arm motor function (ARAT). Diversity-
MID of ARAT; a variance of 98; alpha = 5%; beta = 20%, and a diversity
ontal green line of conventional statistical significance (alpha = 0.05)
ntial monitoring boundary for benefit during the fifth trial. After the
trial sequential monitoring boundary score of 2.33. With 199 out of
pt or reject an effect of CIMT on ARAT, although it looked promising
analysis and the figure were made with the TSA software. Legend.
onitoring boundary for benefit score for single study. Abbreviations:
difference; var, variance; D, diversity; a, alpha; b, beta.
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concerns about the state of science of RCTs that ex-
plored the efficacy of CIMT. The positive finding of
CIMT may have been enhanced by the high percentage
of low quality and small studies. Reporting and publica-
tion biases, particularly the bias towards publishing stud-
ies with positive findings, may have further affected our
results. In fact, our study shows that more recent publi-
cations had less extreme results compared to earlier
studies, such that the latter may present findings that
are out of proportion to the truth [57]. Highly beneficial
results are most tantalizing and attractive to investiga-
tors and editors. Replication studies with intermediate,
potentially less extreme results may then be published,
filling in the gap between the early impressive and the
later modest effects.
Systematic reviews and meta-analyses are considered
to be the best available evidence to inform clinical
decision-making, although the best available evidence
may not be synonymous with ‘sufficient evidence’ or
‘strong evidence’ [12,28]. The interpretation of meta-
analyses should not be simplistic. About 25% of conven-
tional meta-analyses, which include a small number of
events and patients, may falsely report the estimated
intervention effects as statistically significant. Empirical
evidence also shows that large pooled intervention ef-
fects observed in early positive meta-analyses tend to
dissipate as more evidence is accumulated [28]. When a
meta-analysis includes a small number of trials and a
small number of patients, random errors can cause
spurious findings [10]; paucity of studies and patients is
common in the rehabilitation field [58]. To the best of
our knowledge, this study is the first attempt to apply
TSA to the neurorehabilitation field, and demonstrates
TSA to be a useful tool to adjust for random-error risk.
Authors, peer reviewers, and readers should carefully
consider the statistically significant results proposed by
meta-analyses conducted on the early phase of research
on innovative therapies [59].
TSA does present limits. Only trials with the same out-
come measure can be included, thereby excluding a part of
the available information: further TSA techniques should be
developed in order to cumulate standardized MDs, an effect
size which overcomes differences across measures. Our find-
ings should be considered with caution, since they are driven
by assumptions on the MID and can only be generalized to
similar patient populations. An important issue is the way in
which the MID was established. We used a distribution-
based method when the literature did not provide a clear
MID. However, this methodology may not be optimal.
TSA focuses on random error, although bias is also an
important variable that must be considered when recom-
mending an intervention. Most of the included trials fea-
tured a high risk of bias; three were considered to have alower risk of bias. None of the trials were judged to be at a
low risk of bias for all seven domains [24]. Most of the in-
cluded RCTs (11 out of 14 included studies) did not report
allocation concealment. Although the allocation conceal-
ment is known to be an important component of trial de-
sign, Foley et al. [60] underline that most trials in stroke
rehabilitation that were published after the release of the
CONSORT statement did not provide any description of
the concealment of the allocation sequence. Results could
be more conservative if the trials were conducted with a
high methodological quality, taking into account all types
of bias, which are not all reported here. Well-designed tri-
als with a low risk of bias in all seven bias domains [24]
may help conduct more conservative TSAs and produce
more reliable results for quantifying the amount of add-
itional evidence.
Moreover, we extracted data from trials in a previously
published systematic review, without considering the po-
tential availability of new studies since its publication.
We will add these trials to the next update of the meta-
analysis where we intend to conduct TSA on the out-
comes and a Grading of Recommendations Assessment,
Development and Evaluation (GRADE) analysis for the
quality of evidence. The inclusion of additional trials
may show conclusive evidence, suggesting that no further
trials are needed if futility is reached, or that superiority is
proven. Before conducting new trials, investigators should
collect available evidence on past trials and design their
trial against the results of TSA. Recently, some trials
[61,62] have randomized patients to different types of
CIMTs. This assumes that CIMT is effective for patients
with stroke, although there remains insufficient evidence
to firmly establish the intervention’s potential benefits. Ex-
posing patients to a therapy in its infancy exposes them to
risks as the therapy can be ineffective or detrimental. If
new trials are published, it is easy to re-estimate the add-
itional number of patients required to obtain firm evi-
dence in the meta-analysis, thereby guiding trialists about
the optimal sample size to adopt [63,64]. In some cases,
TSA may stop the implementation of trials accumulating
redundant evidence [65].
Conclusions
Evidence on the effects of CIMT reported in our
Cochrane review [4] may be optimistic since the replica-
tion studies conducted in the last years did not confirm
any statistically significant beneficial effects of CIMT.
Publication bias and the appearance of spuriously favor-
able results in the early phase of the accumulation of scien-
tific evidence are well-established problems in biomedical
research [57,66]. High-quality RCTs are needed to resolve
uncertainties surrounding the effectiveness of CIMT. The
risk of random error in meta-analyses is becoming increas-
ingly important as some authors advocate moving towards
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random error in the existing cumulative meta-analysis and
identify the need for future trials. We recommend the use
of TSA along with systematic error assessment tools.
Appendix
MEDLINE (Ovid) search strategy
The following search strategy, which was developed by the
Cochrane Stroke Group Trials Search Coordinator, was
used for the Medical Literature Analysis and Retrieval
System Online database (MEDLINE) (Ovid), and was
adapted for the Cochrane Central Register of Controlled
Trials (CENTRAL):
1. exp cerebrovascular disorders/ or brain injuries/ or
brain injury, chronic/
2. (stroke$ or cva or poststroke or post-stroke).tw.
3. (cerebrovasc$ or cerebral vascular).tw.
4. (cerebral or cerebellar or brain$ or vertebrobasilar).tw.
5. (infarct$ or isch?emi$ or thrombo$ or emboli$ or
apoplexy).tw.
6. 4 and 5
7. (cerebral or brain or subarachnoid).tw.
8. (haemorrhage or hemorrhage or haematoma or
hematoma or bleed$).tw.
9. 7 and 8
10. hemiplegia/ or exp paresis/
11. (hempar$ or hemipleg$ or paresis or paretic or
brain injur$).tw.
12. 1 or 2 or 3 or 6 or 9 or 10 or 11
13. exp upper extremity/
14. (upper limb$ or upper extremit$ or arm or
shoulder or hand or axilla or elbow$ or forearm$ or
finger$ or wrist$).tw.
15. 13 or 14
16. restraint, physical/
17. exercise movement techniques/ or exercise/ or
exercise therapy/
18. immobilization/
19. physical therapy techniques/
20. (constrain$ or restrain$ or immobili$).tw.
21. (mCIMT or CIT or “CI therapy” or “forced use”).tw.
22. recovery of function/
23. splints/ or casts, surgical/
16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
24. 12 and 15 and 24
EMBASE (Ovid) search strategy
The following search strategy was used for the Excerpta
Medica dataBASE (EMBASE) (Ovid):
1. cerebrovascular disease/ or basal ganglion hemorrhage/
or cerebral artery disease/ or cerebrovascular accident/
or stroke/ or exp carotid artery disease/ or exp brainhematoma/ or exp brain hemorrhage/ or exp brain
infarction/ or exp brain ischemia/ or exp intracranial
aneurysm/ or exp occlusive cerebrovascular disease/
or exp brain injury/
2. (stroke$ or cva or poststroke or post-stroke).tw.
3. (cerebrovasc$ or cerebral vasc$).tw.
4. (cerebral or cerebellar or brain$ or vertebrobasilar).tw.
5. (infarct$ or isch?emi$ or thrombo$ or emboli$ or
apoplexy).tw.
6. 4 and 5
7. (cerebral or brain or subarachnoid).tw.
8. (haemorrhage or hemorrhage or haematoma or
hematoma or bleed$).tw.
9. 7 and 8
10. hemiplegia/ or hemiparesis/ or paresis/
11. (hemipleg$ or hemipar$ or paresis or paretic or
brain injur$).tw.
12. 1 or 2 or 3 or 6 or 9 or 10 or 11
13. exp arm/
14. (upper limb$ or upper extremit$ or arm or
shoulder or hand or axilla or elbow$ or forearm$ or
finger$ or wrist$).tw.
15. 13 or 14
16. exp exercise/ or exp kinesiotherapy/ or physiotherapy/
or immobilization/
17. (restrain$ or constrain$ or immobili$).tw.
18. (mCIMT or CIT or CI therapy or “forced use”).tw.
19. dynamic splint/ or plaster cast/ or splint/
20. (splint$ or cast or casts).tw.
21. or/16-20
22. 12 and 15 and 21
CINAHL search strategy
The following search strategy was used for the Cumulative
Index to Nursing and Allied Health Literature database
(CINAHL):
1. exp cerebrovascular disorders/
2. stroke$.tw.
3. cva$.tw.
4. cerebrovasc$.tw.
5. cerebral vascular$.tw.
6. (cerebral or cerebellar or brain$ or vertebrobasilar).
tw.
7. (infarct$ or isch?emi$ or thrombo$ or emboli$ or
vasospasm$ or apople$).tw.
8. 6 and 7
9. (cerebral or intracerebral or intracranial or parenchymal
or brain$ or intraventricular or periventricular or
cerebellar or infratentorial or supratentorial or
subarachnoid).tw.
10. (Haemorrhage or hemorrhage or haematoma or
hematoma or bleed$ or aneurysm).tw.
11. 9 and 10
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13. tia.tw.
14. hemiplegia/
15. brain injuries/ or left hemisphere injuries/ or right
hemisphere injuries/
16. (hemipar$ or hemipleg$ or paresis or paretic or
brain injur$).tw.
17. 1 or 2 or 3 or 4 or 5 or 8 or 11 or 12 or 13 or 14
or 15 or 16
18. exp arm/
19. (upper limb$ or upper extremit$ or arm or
shoulder or hand or axilla or elbow$ or forearm$ or
finger$ or wrist$).tw.
20. 18 or 19
21. Restraint, Physical/
22. Immobilization/
23. “Taping and Strapping”/
24. exp Exercise/
25. exp Therapeutic Exercise/
26. Physical Therapy/mt [Methods]
27. splints/ or slings/ or casts/
28. “Task Performance and Analysis”/
29. (constrain$ or restrain$ or immobil$).tw.
30. (mCIMT or CIT or “CI therapy” or “forced use”).tw.
31. 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29
or 30
32. 17 and 20 and 31
PEDro search strategy
The following search strategy was used for the Physio-
therapy Evidence Database (PEDro):
PEDro is a web-based database of randomized con-
trolled trials and systematic reviews relevant to physio-
therapy. The following search strategy was used.
Abstract and Title: constraint, stroke, cva, poststroke,
hemi, brain injur, *matoma, bleed, cerebrovasc, cerebral,
brain, infarct, thrombo.
Body part: upper arm, shoulder or shoulder girdle/
forearm or elbow/hand or wrist.
All search terms in the title or abstract were combined
with body part descriptors using the AND operator.
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